Your browser is no longer supported. Please, upgrade your browser.
ABIO ARCA biopharma, Inc. monthly Stock Chart
ABIO [NASD]
ARCA biopharma, Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own0.20% Shs Outstand9.32M Perf Week9.00%
Market Cap38.75M Forward P/E- EPS next Y- Insider Trans- Shs Float9.29M Perf Month9.56%
Income-5.80M PEG- EPS next Q- Inst Own8.50% Short Float0.45% Perf Quarter-22.63%
Sales- P/S- EPS this Y59.80% Inst Trans56.66% Short Ratio0.06 Perf Half Y-53.36%
Book/sh8.35 P/B0.51 EPS next Y- ROA-29.30% Target Price- Perf Year-24.29%
Cash/sh5.59 P/C0.76 EPS next 5Y- ROE-31.30% 52W Range2.21 - 22.00 Perf YTD-25.75%
Dividend- P/FCF- EPS past 5Y41.30% ROI- 52W High-80.73% Beta2.84
Dividend %- Quick Ratio34.00 Sales past 5Y- Gross Margin- 52W Low91.86% ATR0.20
Employees9 Current Ratio34.00 Sales Q/Q- Oper. Margin- RSI (14)55.96 Volatility6.30% 4.65%
OptionableYes Debt/Eq0.00 EPS Q/Q56.70% Profit Margin- Rel Volume0.57 Prev Close4.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume665.09K Price4.24
Recom- SMA206.53% SMA501.08% SMA200-15.06% Volume380,550 Change-0.93%
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Nov-23-20 12:28PM  
08:30AM  
Nov-02-20 08:30AM  
Oct-07-20 08:30AM  
Oct-05-20 04:30PM  
Sep-21-20 08:00AM  
Aug-17-20 08:49AM  
Aug-12-20 08:00AM  
Aug-05-20 04:15PM  
Jul-07-20 08:30AM  
Jun-03-20 09:56AM  
09:56AM  
Jun-01-20 08:20AM  
May-29-20 12:24PM  
09:59AM  
May-28-20 04:19PM  
12:14PM  
10:27AM  
08:00AM  
May-07-20 08:30AM  
May-06-20 04:30PM  
Feb-18-20 04:30PM  
Feb-01-20 08:31AM  
Nov-06-19 04:10PM  
Nov-03-19 08:47AM  
Sep-12-19 08:30AM  
Sep-11-19 08:30AM  
Sep-04-19 01:37PM  
Aug-21-19 09:49AM  
Aug-01-19 04:30PM  
Jun-04-19 07:09AM  
May-13-19 09:00AM  
May-08-19 04:30PM  
May-01-19 08:30AM  
Apr-23-19 08:30AM  
Mar-18-19 08:30AM  
Mar-06-19 08:00AM  
Feb-27-19 04:15PM  
Feb-20-19 07:30AM  
Jan-16-19 08:30AM  
Dec-26-18 11:47AM  
Dec-20-18 04:01PM  
Nov-14-18 04:30PM  
Nov-12-18 08:30AM  
Nov-05-18 08:30AM  
Oct-10-18 04:16PM  
Oct-02-18 08:00AM  
Sep-18-18 08:30AM  
Aug-09-18 04:15PM  
Aug-03-18 09:45AM  
Jul-31-18 12:15PM  
08:30AM  
08:10AM  
Jun-19-18 07:05AM  
May-29-18 08:30AM  
May-11-18 08:20AM  
May-10-18 08:30AM  
07:15AM  
May-08-18 04:15PM  
Apr-23-18 08:30AM  
Apr-03-18 07:20AM  
Mar-22-18 04:30PM  
Feb-27-18 03:00PM  
Feb-26-18 02:18PM  
08:00AM  
Jan-23-18 05:13PM  
Jan-08-18 08:30AM  
Jan-02-18 05:09PM  
Dec-08-17 06:13PM  
Nov-30-17 02:25PM  
Nov-20-17 08:05AM  
Nov-17-17 08:10AM  
Nov-16-17 08:30AM  
Nov-09-17 04:05PM  
Oct-23-17 08:16PM  
Sep-21-17 08:30AM  
Aug-16-17 08:30AM  
Aug-09-17 04:30PM  
Aug-03-17 04:15PM  
Jun-20-17 08:30AM  
May-15-17 08:30AM  
Apr-26-17 08:30AM  
Apr-18-17 08:30AM  
Mar-25-17 01:04PM  
Mar-21-17 04:46PM  
04:30PM  
04:10PM  
Mar-06-17 04:32PM  
08:30AM  
Mar-01-17 04:47PM  
Feb-21-17 08:46AM  
08:30AM  
Jan-18-17 04:32PM  
08:30AM  
Jan-11-17 04:54PM  
Jan-04-17 08:30AM  
Dec-20-16 02:26PM  
Nov-15-16 08:30AM  
Nov-14-16 05:19PM  
05:08PM  
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EChairman of the BoardSep 25Buy4.285,00021,40020,000Sep 25 04:20 PM
CONWAY ROBERT EChairman of the BoardSep 22Buy4.663,05614,24115,000Sep 24 04:20 PM
CONWAY ROBERT EChairman of the BoardSep 21Buy4.7710,00047,66011,944Sep 21 05:00 PM